BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions
路透社2026/10/07 14:16October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)
October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87
** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash
** The company obtained this voucher after the FDA approved its drug Genglycos (link) for the treatment of type Ia glycogen storage disease (also known as Von Gierke disease)
** According to the licensing agreement, after the deal is completed, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health
** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet responded
** The recommended retail price of Genglycos in the United States is $2.7 million per patient
** As of the close of the previous trading day, the stock had fallen about 35% year to date
(To support non-native English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or lack necessary context, and Reuters does not guarantee the accuracy of the translated text. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss caused by the use of its automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Federal Reserve officials: Not enough progress seen in reducing inflation
Data: ETH Falls Below $2550
Moody’s gives Sky Protocol B3 rating as institutional interest in USDS grows
Brent crude oil falls to $104 per barrel, down 0.2% in 24 hours.
Crypto prices
More
